ExodusPoint Capital Management’s Mineralys Therapeutics MLYS Stock Holding History

ExodusPoint Capital Management’s Portfolio MLYS Stock Details MLYS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$2.73M	Buy	+101,052	New	+$2.77M	0.02%	700
2025 Q4	–	Sell	-6,670	Closed	-$253K	–	1860
2025 Q3	$253K	Sell	6,670 -165,882	-96%	-$3.59M	﹤0.01%	1339
2025 Q2	$2.33M	Buy	+172,552	New	+$2.5M	0.02%	687
2024 Q3	–	Sell	-274,316	Closed	-$3.21M	–	1904
2024 Q2	$3.21M	Buy	274,316 +152,110	+124%	+$1.92M	0.02%	598
2024 Q1	$1.58M	Buy	122,206 +48,266	+65%	+$596K	0.01%	798
2023 Q4	$636K	Sell	73,940 -85,501	-54%	-$671K	﹤0.01%	966
2023 Q3	$1.52M	Sell	159,441 -34,084	-18%	-$444K	0.01%	788
2023 Q2	$3.3M	Buy	193,525 +12,213	+7%	+$183K	0.03%	599
2023 Q1	$2.84M	Buy	+181,312	New	+$3.05M	0.02%	742

Other funds holding MLYS

Catalys Pacific Tokyo, Japan $229M AUM 100.3% 1-Year Est. Return

RCM

RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Samsara BioCapital Palo Alto, California $1.22B AUM 242.83% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

LCM

Laurion Capital Management New York $3.9B AUM 75.03% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

ExodusPoint Capital Management's MLYS Position: Q2 2026 in Review

ExodusPoint Capital Management opened a new position in Mineralys Therapeutics (MLYS) in Q2 2026: 101,052 shares worth $2.73M. The stake represents 0.02% of the portfolio and ranks #700 among its holdings. This is a return to the name: ExodusPoint Capital Management previously reported a position in MLYS as recently as Q3 2025.

ExodusPoint Capital Management first reported a position in MLYS in Q1 2023 and has held it in 9 quarters since. The position peaked at $3.3M in Q2 2023. 226 funds tracked by Wall St. Rank hold MLYS as of Q2 2026.

ExodusPoint Capital Management held 101,052 shares of Mineralys Therapeutics worth $2.73M as of Q2 2026.
Mineralys Therapeutics was a new ExodusPoint Capital Management position in Q2 2026.
Mineralys Therapeutics made up 0.02% of ExodusPoint Capital Management's portfolio in Q2 2026, its #700 holding.
ExodusPoint Capital Management first reported a position in Mineralys Therapeutics in Q1 2023 and has held it in 9 quarters since.
ExodusPoint Capital Management's Mineralys Therapeutics position peaked at $3.3M in Q2 2023.
226 funds tracked by Wall St. Rank held Mineralys Therapeutics as of Q2 2026.

Based on ExodusPoint Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.